ClinicalTrials.gg
CompletedNCT07145892Updated Aug 28, 2025

Three-dimensional Digital Breast Tomosynthesis Versus Digital Mammography

An observational study in Three Dimension, Digital Tomosynthesis and Digital Mammography, sponsored by The General Authority for Teaching Hospitals and Institutes. Completed at 1 site in Egypt. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by The General Authority for Teaching Hospitals and Institutes · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
255
Ages
30 Years and older
Sex
Female
01

Study summary

This study aimed to compare the supremacy of (3D) tomosynthesis versus (2D) digital mammography in the diagnosis of benign breast lesions in asymptomatic females.

Read the detailed description

Most of the breast lesions are benign, but much concern is given to malignant lesions because breast cancer is the most common malignancy in women.

Mammography is the only study for screening in asymptomatic patients, and it is the initial imaging study in the diagnosis of symptomatic patients, with a sensitivity for suspicious lesions of 86% and a specificity of 57%.

In recent years, a significant effort has been expended to develop new approaches to breast imaging, one of which is the use of digital breast tomosynthesis (DBT), which is a pseudo three-dimensional digital mammography system that produces a series of thin-section reconstructed images from low-dose X-ray projections at multiple angles.

02

Conditions studied

  • Three Dimension
  • Digital Tomosynthesis
  • Digital Mammography
  • Diagnosis
  • Benign Breast Lesions
  • Asymptomatic Females

Browse trials for

03

In context

Lead sponsor

The General Authority for Teaching Hospitals and Institutes is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective study was conducted on patients referred to the Diagnostic Radiology Department at Damanhur Educational Hospital and Tanta University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Women with benign breast lesions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating female.
  • Patients who refuse to fill the consent form.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
255 participants (actual)
Patient registry
No

Groups and cohorts

  • Group I

    Categorized 130 women aged from 30 to 40 years.

    Device: Three-dimensional Digital Breast Tomosynthesis · Device: Two-dimensional Digital Mammography

  • Group II

    Categorized 115 women aged from 40 to 50 years.

    Device: Three-dimensional Digital Breast Tomosynthesis · Device: Two-dimensional Digital Mammography

  • Group III

    Categorized 10 females aged above 50 years.

    Device: Three-dimensional Digital Breast Tomosynthesis · Device: Two-dimensional Digital Mammography

Interventions

  • DeviceThree-dimensional Digital Breast Tomosynthesis

    Patients underwent three-dimensional digital breast tomosynthesis.

  • DeviceTwo-dimensional Digital Mammography

    Patients underwent two-dimensional digital mammography

06

What researchers measure

Primary outcomes

  1. Correlation between imaging findings and the final diagnosis

    Correlation between imaging findings and the final diagnosis was calculated.

    Time frame: 6 months post-procedure

07

Study locations

1 site
  • General Authority for Teaching Hospitals and Institutes
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in May 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartActual
Jun 1, 2024
Primary completionActual
May 29, 2025
CompletionActual
May 29, 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145892
Lead sponsor
The General Authority for Teaching Hospitals and Institutes
Responsible party
Hekmat Samir Baumey (Lecturer of Diagnostic Radiology, Damnhour National Medical Institute, The General Authority for Teaching Hospitals and Institutes) — Principal investigator
First posted
Aug 28, 2025
Start date
Jun 1, 2024
Primary completion
May 29, 2025
Completion
May 29, 2025
Last update
Aug 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion